236 related articles for article (PubMed ID: 38788451)
1. mRNA vaccines against infectious diseases and future direction.
Aleem MT; Munir F; Shakoor A; Gao F
Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
[TBL] [Abstract][Full Text] [Related]
2. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
Jawalagatti V; Kirthika P; Lee JH
Front Immunol; 2022; 13():884862. PubMed ID: 35592330
[TBL] [Abstract][Full Text] [Related]
3. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
Kutikuppala LVS; Kourampi I; Kanagala RSD; Bhattacharjee P; Boppana SH
Med Sci (Basel); 2024 May; 12(2):. PubMed ID: 38804384
[TBL] [Abstract][Full Text] [Related]
4. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
Vadovics M; Muramatsu H; Sárközy A; Pardi N
Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
[TBL] [Abstract][Full Text] [Related]
5. Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.
Zimmermann L; Erbar S
Methods Mol Biol; 2024; 2786():135-144. PubMed ID: 38814392
[TBL] [Abstract][Full Text] [Related]
6. Cancer mRNA vaccines: clinical advances and future opportunities.
Sayour EJ; Boczkowski D; Mitchell DA; Nair SK
Nat Rev Clin Oncol; 2024 Jul; 21(7):489-500. PubMed ID: 38760500
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 mRNA vaccines.
Huang Q; Zeng J; Yan J
J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
[TBL] [Abstract][Full Text] [Related]
8. Introduction to RNA Vaccines Post COVID-19.
Kramps T
Methods Mol Biol; 2024; 2786():1-22. PubMed ID: 38814388
[TBL] [Abstract][Full Text] [Related]
9. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
Chaudhary N; Weissman D; Whitehead KA
Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
[TBL] [Abstract][Full Text] [Related]
10. Rational design of a single-component mRNA vaccine against orthopoxvirus and SARS-CoV-2.
Yang Y; Zhao X; Li Y; Zai X; Wang X; Zhang Y; Wang X; Lv P; Zhang J; Hou L; Xu J; Chen W
Sci China Life Sci; 2024 Jun; 67(6):1311-1313. PubMed ID: 38443664
[No Abstract] [Full Text] [Related]
11. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
[TBL] [Abstract][Full Text] [Related]
12. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
13. Current Developments and Challenges of mRNA Vaccines.
Chen J; Chen J; Xu Q
Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177
[TBL] [Abstract][Full Text] [Related]
14. What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases.
Park JK; Lee EB; Winthrop KL
Ann Rheum Dis; 2024 May; 83(6):687-695. PubMed ID: 38413167
[TBL] [Abstract][Full Text] [Related]
15. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
16. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
17. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
[TBL] [Abstract][Full Text] [Related]
18. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
19. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
Front Immunol; 2022; 13():811802. PubMed ID: 35250985
[TBL] [Abstract][Full Text] [Related]
20. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
